Perplexity AI forecasts Moderna stock at $180 to $240 by the end of 2026, with a $210 bullish base case. The prediction centers on Intismeran, a personalized mRNA cancer vaccine that Perplexity identifies as the dominant valuation driver. A single trial readout reportedly doubled a company's market value in one session, and Perplexity expects the rerating to continue.
This item was indexed from its published source and tied to the entity records it names. The Counterparty reports what the market says and who it says it about; it does not rewrite the original report. Read the source for the full account.